Clinical Trial Update: Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS [Phase 3]

View source ↗

Summary

Phase 3 PEARLS trial evaluating a PPAR-gamma agonist for metabolic syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Snippet

Sponsor: Medstar Health Research Institute | Conditions: Metabolic Syndrome | Phase 3 | Status: TERMINATED